PRVCF
PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; BSV Peptide Program for targeting cancer progression; Non-Addictive Analgesic for pain management; and Dual Gene Therapy for type 2 diabetes and obesity. The company also develops a range of medicinal cannabis-based products. PreveCeutical Medical Inc. is headquartered in Vancouver, Canada.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | 0.00 | $0 | -$533,953 |
| 2025 Q3 | -0.00 | $0 | -$521,196 |
| 2025 Q2 | -0.00 | $0 | -$563,211 |
| 2025 Q1 | -0.00 | $0 | -$161,824 |
| 2024 Q4 | -0.00 | $0 | -$66,630 |
| 2024 Q3 | -0.00 | $0 | -$111,898 |
| 2024 Q2 | -0.00 | $0 | -$190,767 |
| 2024 Q1 | -0.00 | $0 | -$59,197 |